Apr 07, 2014 at 10:31 | Source: Moneycontrol.com
The first question facing observers would be whether Sun would be able to help Ranbaxy get past its troubles with the US FDA, which has now stopped imports into the US from all four of its manufacturing plants in India.
Apr 02, 2014 at 07:46 | Source: Reuters
The S&P 500 has gained for three straight sessions, up about 2 percent over that period.
Apr 01, 2014 at 21:05 | Source: PTI
According to sources, Mistry in his annual address to employees of Tata Motors, including overseas subsidiaries, also said "every function, right from design, purchasing, manufacturing to sales, will need to work hard and seamlessly to help us bounce back strongly."
Mar 13, 2014 at 18:59 | Source: PTI
The GJF represents over 6,00,000 members comprising manufacturers, wholesalers, retailers, distributors, labs, gemologists, designers and allied services among others.
Mar 07, 2014 at 07:48 | Source: Reuters
Weekly applications for US unemployment insurance fell to 323,000, the lowest in three months, a sign of strength in a labor market that has been hobbled by severe weather. New orders for US factory goods, however, fell more than expected in January and shipments also slipped, adding to signs of a recent slowdown in manufacturing activity.
Mar 06, 2014 at 19:45 | Source: Reuters
An Indian committee is reviewing up to a dozen patented drugs to see if so-called compulsory licences, which in effect break exclusivity rights, can be issued for some of them, two senior government officials said last month.
Feb 28, 2014 at 11:39 | Source: Moneycontrol.com
Jubilant Life Sciences has received a communication from the US Food and Drug Administration (FDA), classifying its pharmaceutical manufacturing facility at Montreal, Canada as acceptable.
Feb 28, 2014 at 09:35 | Source: Moneycontrol.com
Jubilant Life Sciences announced today that it has received a communication from the US Food and Drug Administration (FDA), classifying its pharmaceutical manufacturing facility at Montreal, Canada as Acceptable. This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications.
Feb 25, 2014 at 17:46 | Source: Reuters
New Delhi is furious about a threat of trade sanctions made by the U.S. Trade Representative's (USTR) office over its protection of intellectual property rights (IPR), preference for domestic producers and non-trade barriers.
Feb 25, 2014 at 08:50 | Source: Reuters
In January, the US Food and Drug Administration banned the Toansa plant, a key supplier of ingredients to the generic drugmaker's US factory, from sending its products to the United States due to manufacturing violations.